{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T03:44:02Z","timestamp":1794368642390,"version":"4.9.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11033-025-10862-z","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T12:17:19Z","timestamp":1753445839000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The effect of CYP3A4, CYP3A5 and MDR1 (ABCB1) single nucleotide polymorphisms on the pharmacokinetics of cyclosporine in Algerian stable renal transplant recipients"],"prefix":"10.1007","volume":"52","author":[{"given":"Maya","family":"Bouafia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed El Amine","family":"Smaali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souheila","family":"Zemmouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Boumegoura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selwa","family":"Bellara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayomide Victor","family":"Atoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raid","family":"Serrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Bouhedjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Messaoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noureddine","family":"Abadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Habib","family":"Belmahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"10862_CR1","first-page":"153","volume":"492","author":"JYX Wei","year":"2023","unstructured":"Wei JYX, Gao J, Wang C, Wei W et al (2023) Role of cyclosporin A in the treatment of kidney disease and nephrotoxicity. Toxicology 492:153\u2013544","journal-title":"Toxicology"},{"key":"10862_CR2","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2217\/pgs-2017-0127","volume":"18","author":"B Sun","year":"2017","unstructured":"Sun B, Guo Y, Gao J, Shi W, Fan C, Li X, Qiu J, Qin Y, Liu G et al (2017) Influence of CYP3A and ABCB1 polymorphisms on cyclosporine concentrations in renal transplant recipients. Pharmacogenomics 18:1503\u20131513","journal-title":"Pharmacogenomics"},{"key":"10862_CR3","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/ki.2009.377","volume":"77","author":"BL Kasiske","year":"2009","unstructured":"Kasiske BL, Zeier MG, Chapman RJ, Craig CJ, Ekberg H, Garvey AC, Green MD, Jha V, Josephson MA, Kiberd BA, Kreis HA, McDonald RA, Newmann JM, Obrador GT, Vincenti FG, Cheung M, Earley A, Raman G, Abariga S, Balk EM et al (2009) KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int 77:299\u2013311","journal-title":"Kidney Int"},{"key":"10862_CR4","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1016\/j.transproceed.2009.06.155","volume":"41","author":"E Rodrigo","year":"2009","unstructured":"Rodrigo E, Ruiz J, De Cos MA, Rui J, Gago M, Pi\u00f1era C, S\u00e1nchez B, Gonz\u00e1lez-Cotorruelo J, G\u00f3mez-Alamillo C, Arias M et al (2009) Correlation of C0 and C2 levels with cyclosporine side effects in kidney transplantation. Transpl Proc 41:2328\u20132331","journal-title":"Transpl Proc"},{"key":"10862_CR5","doi-asserted-by":"crossref","unstructured":"Kong Q, Gao N, Wang Y, Hu G, Qian J, Chen B et al (2023) Functional evaluation of cyclosporine metabolism by CYP3A4 variants and potential drug interactions. Front Pharmacol 13","DOI":"10.3389\/fphar.2022.1044817"},{"key":"10862_CR6","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.2217\/pgs.11.90","volume":"12","author":"L Elens","year":"2011","unstructured":"Elens L, Van Schaik RH, Panin N, De Meyer M, Wallemacq P, Lison D, Mourad M, Haufroid V et al (2011) Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors\u2019 dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics 12:1383\u20131396","journal-title":"Pharmacogenomics"},{"issue":"2","key":"10862_CR7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.retram.2020.02.001","volume":"68","author":"NK Zgheib","year":"2020","unstructured":"Zgheib NK, Alameddine R, Massoud R, Nasr R, Zahreddine A, Cheikh JE, Mahfouz R, Bazarbachi A et al (2020) The role of candidate genetic polymorphisms in the interaction between voriconazole and cyclosporine in patients undergoing allogeneic hematopoietic cell transplantation: an explorative study. Curr Res Translational Med 68(2):51\u201358","journal-title":"Curr Res Translational Med"},{"issue":"9","key":"10862_CR8","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1345\/aph.1R004","volume":"46","author":"J Song","year":"2012","unstructured":"Song J, Kim MG, Choi B, Han NY, Yun H, Yoon J, Oh J et al (2012) CYP3A5 polymorphism effect on cyclosporine pharmacokinetics in living donor renal transplant recipients: analysis by population pharmacokinetics. Ann Pharmacother 46(9):1141\u20131151","journal-title":"Ann Pharmacother"},{"issue":"26","key":"10862_CR9","doi-asserted-by":"crossref","first-page":"e16113","DOI":"10.1097\/MD.0000000000016113","volume":"98","author":"L Su","year":"2019","unstructured":"Su L, Yin L, Yang J, Sun L et al (2019) Correlation between gene polymorphism and blood concentration of calcineurin inhibitors in renal transplant recipients. Medicine 98(26):e16113","journal-title":"Medicine"},{"key":"10862_CR10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/FPC.0000000000000516","volume":"34","author":"AI Ebid","year":"2023","unstructured":"Ebid AI, Ismail DA, Lotfy NM et al (2023) Effect of CYP3A422, CYP3A53 and POR28 polymorphisms on calcineurin inhibitor dose requirements in early renal transplant patients. Pharmacogenet Genomics 34:43\u201352","journal-title":"Pharmacogenet Genomics"},{"issue":"10","key":"10862_CR11","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/FPC.0b013e328364db84","volume":"23","author":"JM Barbarino","year":"2013","unstructured":"Barbarino JM, Staatz CE, Venkataramanan R, Klein TE, Altman RB et al (2013) PharmGKB summary: cyclosporine and tacrolimus pathways. Pharmacogenet Genomics 23(10):563\u2013585","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"10862_CR12","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.ackd.2019.08.006","volume":"27","author":"SS Farouk","year":"2020","unstructured":"Farouk SS, Rein JL et al (2020) The many faces of calcineurin inhibitor Toxicity-What the FK? Adv Chronic Kidney Dis 27(1):56\u201366","journal-title":"Adv Chronic Kidney Dis"},{"issue":"6","key":"10862_CR13","doi-asserted-by":"crossref","first-page":"479","DOI":"10.4196\/kjpp.2013.17.6.479","volume":"17","author":"JS Lee","year":"2013","unstructured":"Lee JS, Cheong HS, Kim LH, Kim JO, Seo DW, Kim YH, Chung MW, Han SY, Shin HD et al (2013) Screening of genetic polymorphisms of CYP3A4 and CYP3A5 genes. Korean J Physiol Pharmacol 17(6):479","journal-title":"Korean J Physiol Pharmacol"},{"key":"10862_CR14","first-page":"112","volume":"33","author":"M AlMasri","year":"2022","unstructured":"AlMasri M, Qudah Z, Hilal et al (2022) Association between CYP3A41B, CYP3A422 and CYP3A53 polymorphisms and cyclosporine pharmacokinetics in Jordanian kidney transplant patients. Pharmacogenet Genomics 33:112\u2013120","journal-title":"Pharmacogenet Genomics"},{"key":"10862_CR15","doi-asserted-by":"crossref","first-page":"146007","DOI":"10.1016\/j.gene.2021.146007","volume":"809","author":"Y Dong","year":"2021","unstructured":"Dong Y, Xu Q, Li R, Tao Y, Zhang Q, Li J, Ma Z, Shen C, Zhong M, Wang Z, Qiu X et al (2021) CYP3A7, CYP3A4, and CYP3A5 genetic polymorphisms in recipients rather than donors influence tacrolimus concentrations in the early stages after liver transplantation. Gene 809:146007","journal-title":"Gene"},{"issue":"6","key":"10862_CR16","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/clpt.2011.336","volume":"91","author":"K Klein","year":"2012","unstructured":"Klein K, Thomas M, Winter S, Nussler AK, Niemi M, Schwab M, Zanger UM et al (2012) PPARA: A novel genetic determinant of CYP3A4 in vitro and in vivo. Clin Pharmacol Ther 91(6):1044\u20131052","journal-title":"Clin Pharmacol Ther"},{"key":"10862_CR17","doi-asserted-by":"crossref","first-page":"11327","DOI":"10.3390\/ijms252011327","volume":"25","author":"MJ Garc\u00eda-S\u00e1nchez","year":"2024","unstructured":"Garc\u00eda-S\u00e1nchez MJ, Caro-Tarrag\u00f3 A, Ba\u00f1os-Pel\u00e1ez M et al (2024) Genetic variants in CYP3A4 and CYP3A5 genes and their impact on calcineurin inhibitors in kidney transplantation. Int J Mol Sci 25:11327","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10862_CR18","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1111\/j.1440-1681.2006.04492.x","volume":"33","author":"Y Hu","year":"2006","unstructured":"Hu Y, Qiu W, Liu Z, Zhao-Qian L, Li-Jun Z, Tu J, Wang D, Li Z, He J, Zhong G, Zhou G, Zhou H et al (2006) Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation. Clin Exp Pharmacol Physiol 33(11):1093\u20131098","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"4","key":"10862_CR19","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1034\/j.1600-6143.2003.00077.x","volume":"3","author":"H Zheng","year":"2003","unstructured":"Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Bowman P, Boyle G, Law Y, Miller S, Lamba J, Burckart GJ et al (2003) Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 3(4):477\u2013483","journal-title":"Am J Transplant"},{"issue":"3","key":"10862_CR20","doi-asserted-by":"crossref","first-page":"36","DOI":"10.12659\/AOT.883456","volume":"17","author":"L P\u0105czek","year":"2012","unstructured":"P\u0105czek L et al (2012) Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients. Ann Transplant 17(3):36\u201344","journal-title":"Ann Transplant"},{"key":"10862_CR21","doi-asserted-by":"publisher","first-page":"Article1592134","DOI":"10.3389\/fphar.2025.1592134","volume":"16","author":"LY Xajil-Ramos","year":"2025","unstructured":"Xajil-Ramos LY, G\u00e1ndara-Mireles JA, Rosales RJV, Garc\u00eda OKS, Toledo AMR, De la Cruz AKA, Lares-Asseff I, Patr\u00f3n-Romero L, Almanza-Reyes H, Lou-Meda R et al (2025) Impact of CYP3A5 1 and 3 single nucleotide variants on tacrolimus pharmacokinetics and graft rejection risk in pediatric kidney transplant patients. Front Pharmacol 16:Article1592134. https:\/\/doi.org\/10.3389\/fphar.2025.1592134","journal-title":"Front Pharmacol"},{"issue":"1","key":"10862_CR22","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4314\/ahs.v24i1.36","volume":"24","author":"M Ammour","year":"2024","unstructured":"Ammour M, Aberkane A, Boudjema W, Boughrara SM, Benchekor et al (2024) The frequencies distribution of CYP3A5 rs776746 and ABCB1 rs1045642 polymorphisms in the West Algerian population and relationships with pharmacogenetics. Afr Health Sci 24(1):307\u2013312","journal-title":"Afr Health Sci"},{"issue":"2","key":"10862_CR23","doi-asserted-by":"crossref","first-page":"393","DOI":"10.34172\/apb.2023.038","volume":"13","author":"EJ Hagh","year":"2022","unstructured":"Hagh EJ, Mousavi A, Hejazian SM, Haghi M, Esfahanian S, Ahmadian E, Vahed SZ, Ardalan M et al (2022) The impact of single nucleotide polymorphisms on the pharmacokinetics of tacrolimus in kidney allograft recipients of Northern-West, Iran. Adv Pharm Bull 13(2):393\u2013398","journal-title":"Adv Pharm Bull"},{"issue":"2","key":"10862_CR24","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1345\/aph.10380","volume":"36","author":"M Garc\u00eda-S\u00e1iz","year":"2002","unstructured":"Garc\u00eda-S\u00e1iz M, L\u00f3pez-Gil A, Alfonso I, Boada JN, Armijo JA et al (2002) Factors influencing cyclosporine blood Concentration-Dose ratio. Ann Pharmacother 36(2):193\u2013199","journal-title":"Ann Pharmacother"},{"issue":"9","key":"10862_CR25","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/00008571-200112000-00005","volume":"11","author":"E Hustert","year":"2001","unstructured":"Hustert E, Haberl M, Burk O, Wolbold R, He Y, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, Koch I, Zibat A, Brockm\u00f6ller J, Halpert JR, Zanger UM, Wojnowski L et al (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11(9):773\u2013779","journal-title":"Pharmacogenetics"},{"issue":"4","key":"10862_CR26","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","volume":"27","author":"P Kuehl","year":"2001","unstructured":"Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E et al (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27(4):383\u2013391","journal-title":"Nat Genet"},{"issue":"5","key":"10862_CR27","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.clpt.2004.01.009","volume":"75","author":"D Anglicheau","year":"2004","unstructured":"Anglicheau D, Thervet E, Etienne I, De Ligny BH, Meur LY, Touchard G, B\u00fcchler M, Laurent-Puig P, Tregouet D, Beaune P, Daly A, Legendre C, Marquet P et al (2004) CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 75(5):422\u2013433","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10862_CR28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cpt.113","volume":"98","author":"K Birdwell","year":"2015","unstructured":"Birdwell K, Decker B, Barbarino J, Peterson J, Stein C, Sadee W, Wang D, Vinks A, He Y, Swen J, Leeder J, Van Schaik R, Thummel K, Klein T, Caudle K, MacPhee I et al (2015) Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther 98(1):19\u201324","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10862_CR29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/00365521.2013.848231","volume":"49","author":"K B\u00e1lint","year":"2013","unstructured":"B\u00e1lint K, Farkas M, Sz\u0170cs Z, Szepes F, Nagy T, Wittmann T, Moln\u00e1r et al (2013) Long-term increase in serum cholesterol levels in ulcerative colitis patients treated with cyclosporine: an underdiagnosed side effect frequently associated with other drug-related complications. Scand J Gastroenterol 49(1):59\u201365","journal-title":"Scand J Gastroenterol"},{"issue":"06","key":"10862_CR30","doi-asserted-by":"crossref","first-page":"466","DOI":"10.5414\/CP201836","volume":"51","author":"D Li","year":"2013","unstructured":"Li D, Teng R, Zhu H, Fang Y et al (2013) CYP3A4\/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients. Int J Clin Pharmacol Ther 51(06):466\u2013474","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"3","key":"10862_CR31","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/11317350-000000000-00000","volume":"49","author":"CE Staatz","year":"2010","unstructured":"Staatz CE, Goodman LK, Tett SE et al (2010) Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. Clin Pharmacokinet 49(3):141\u2013175","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10862_CR32","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/FTD.0b013e31818a2a60","volume":"30","author":"S Crettol","year":"2008","unstructured":"Crettol S, Venetz J, Fontana M, Aubert J, Pascual M, Eap CB et al (2008) CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients. Ther Drug Monit 30(6):689\u2013699","journal-title":"Ther Drug Monit"},{"key":"10862_CR33","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ejps.2015.05.011","volume":"76","author":"XR Tao","year":"2015","unstructured":"Tao XR, Xia XY, Zhang J et al (2015) CYP3A4*18B and CYP3A5*3 polymorphisms contribute to Pharmacokinetic variability of cyclosporine among healthy Chinese subjects. Eur J Pharm Sci 76:238\u2013244","journal-title":"Eur J Pharm Sci"},{"issue":"6","key":"10862_CR34","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00228-014-1656-3","volume":"70","author":"S Lunde","year":"2014","unstructured":"Lunde S, Bremer K, Midtvedt B, Mohebi M, Dahl S, Bergan A, \u00c5sberg H, Christensen et al (2014) The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients. Eur J Clin Pharmacol 70(6):685\u2013693","journal-title":"Eur J Clin Pharmacol"},{"key":"10862_CR35","doi-asserted-by":"crossref","first-page":"674117","DOI":"10.3389\/fphar.2021.674117","volume":"12","author":"S Contreras-Castillo","year":"2021","unstructured":"Contreras-Castillo S, Plaza A, Stojanova J, Navarro G, Carmona R, Corval\u00e1n F, Cerpa L, Sandoval C, Mu\u00f1oz D, Leiva M, Casta\u00f1eda LE, Farias N, Alvarez C, Llull G, Mezzano S, Ardiles L, Varela N, Rodr\u00edguez MS, Flores C, Qui\u00f1ones LA et al (2021) Effect of CYP3A4, CYP3A5, MDR1 and POR genetic polymorphisms in immunosuppressive treatment in Chilean kidney transplanted patients. Front Pharmacol 12:674117","journal-title":"Front Pharmacol"},{"key":"10862_CR36","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41525-022-00281-5","volume":"7","author":"PV Jithesh","year":"2022","unstructured":"Jithesh PV, Abuhaliqa M, Syed N, Ahmed I, Anbari ME, Bastaki K, Sherif S, Umlai U, Jan Z, Gandhi G, Manickam C, Selvaraj S, George C, Bangarusamy D, Abdel-Latif R, Al-Shafai M, Tatari-Calderone Z, Estivill X, Pirmohamed M, Yasin H et al (2022) A population study of clinically actionable genetic variation affecting drug response from the middle East. Npj Genomic Med 7:10","journal-title":"Npj Genomic Med"},{"issue":"1","key":"10862_CR37","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ekir.2019.09.013","volume":"5","author":"N Prasad","year":"2019","unstructured":"Prasad N, Jaiswal A, Behera MR, Agarwal V, Kushwaha R, Bhadauria D, Kaul A, Gupta A et al (2019) Melding Pharmacogenomic effect of MDR1 and CYP3A5 gene polymorphism on tacrolimus dosing in renal transplant recipients in Northern India. Kidney Int Rep 5(1):28\u201338","journal-title":"Kidney Int Rep"},{"issue":"3","key":"10862_CR38","doi-asserted-by":"crossref","first-page":"146","DOI":"10.4103\/0971-4065.70846","volume":"20","author":"T Ashavaid","year":"2010","unstructured":"Ashavaid T, Raje H, Shalia K, Shah B et al (2010) Effect of gene polymorphisms on the levels of calcineurin inhibitors in Indian renal transplant recipients. Indian J Nephrol 20(3):146","journal-title":"Indian J Nephrol"},{"issue":"5","key":"10862_CR39","doi-asserted-by":"crossref","first-page":"823","DOI":"10.3390\/jpm12050823","volume":"12","author":"K Sridharan","year":"2022","unstructured":"Sridharan K, Shah S, Jassim A, Hammad M, Gadhban JEA, Segai OA et al (2022b) Evaluation of pharmacogenetics of drug-Metabolizing enzymes and drug efflux transporter in renal transplants receiving immunosuppressants. J Personalized Med 12(5):823","journal-title":"J Personalized Med"},{"issue":"6","key":"10862_CR40","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1093\/clinchem\/47.6.1048","volume":"47","author":"NV Ahsen","year":"2001","unstructured":"Ahsen NV, Richter M, Grupp C, Ringe B, Oellerich M (2001) No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 47(6):1048\u20131052","journal-title":"Clin Chem"},{"issue":"2","key":"10862_CR41","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1399-0012.2006.00635.x","volume":"21","author":"S Fredericks","year":"2007","unstructured":"Fredericks S, Jorga A, MacPhee IA, Reboux S, Shiferaw E, Moreton M, Carter ND, Holt DW, Johnston A et al (2007) Multi-drug resistance gene\u20101 (MDR\u20101) haplotypes and the CYP3A5*1 genotype have no influence on ciclosporin dose requirements as assessed by C0 or C2 measurements. Clin Transplant 21(2):252\u2013257","journal-title":"Clin Transplant"},{"issue":"5","key":"10862_CR42","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1742-7843.2008.00300.x","volume":"103","author":"Z Jiang","year":"2008","unstructured":"Jiang Z, Wang Y, Xu P, Liu R, Zhao X, Chen F et al (2008) Meta-Analysis of the effect of MDR1 C3435T polymorphism on cyclosporine pharmacokinetics. Basic Clin Pharmacol Toxicol 103(5):433\u2013444","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10862_CR43","doi-asserted-by":"crossref","first-page":"108","DOI":"10.12659\/AOT.914683","volume":"24","author":"MJ Kotowski","year":"2019","unstructured":"Kotowski MJ, Bogacz A, Bartkowiak-Wieczorek J, Tejchman K, Dziewanowski K, Ostrowski M, Czerny B, Grze\u015bkowiak E, Machali\u0144ski B, Sie\u0144ko J et al (2019) Effect of Multidrug-Resistant 1 (MDR1) and CYP3A4*1B polymorphisms on Cyclosporine-Based immunosuppressive therapy in renal transplant patients. Ann Transplant 24:108\u2013114","journal-title":"Ann Transplant"},{"issue":"2","key":"10862_CR44","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/bcpt.12371","volume":"117","author":"J Lee","year":"2014","unstructured":"Lee J, Wang R, Yang Y, Lu X, Zhang X, Wang L, Lou Y et al (2014) The effect of ABCB1 C3435T polymorphism on cyclosporine dose requirements in kidney transplant recipients: A Meta-Analysis. Basic Clin Pharmacol Toxicol 117(2):117\u2013125","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"3","key":"10862_CR45","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00008571-200403000-00002","volume":"14","author":"V Haufroid","year":"2004","unstructured":"Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC, Malaise J, Lison D, Squifflet J, Wallemacq P et al (2004) The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14(3):147\u2013154","journal-title":"Pharmacogenetics"},{"issue":"1","key":"10862_CR46","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11033-014-3747-8","volume":"42","author":"O Sharaki","year":"2014","unstructured":"Sharaki O, Zeid M, Moez P, Zakaria NH, Nassar E et al (2014) Impact of CYP3A4 and MDR1 gene (G2677T) polymorphisms on dose requirement of the cyclosporine in renal transplant Egyptian recipients. Mol Biol Rep 42(1):105\u2013117","journal-title":"Mol Biol Rep"},{"key":"10862_CR47","doi-asserted-by":"crossref","unstructured":"Felipe C.R., De Sandes T.V., Sampaio E.M., Park S., Silva H.T., Pestana J.M. et al (2009) Clinical impact of polymorphisms of transport proteins and enzymes involved in the metabolism of immunosuppressive drugs. Transpl Proc 41(5):1441\u20131455","DOI":"10.1016\/j.transproceed.2009.03.024"},{"key":"10862_CR48","first-page":"53","volume":"231","author":"M Mulka-Gierek","year":"2018","unstructured":"Mulka-Gierek M, Foroncewicz B, P\u0105czek L, Wawi\u00f3rko E, Kami\u0144ska J, Kosieradzki M, Ma\u0142kowski P, Ma\u0142czuk B, Nazarewski S, Mucha K et al (2018) Nonsteroidal Anti-Inflammatory drugs and analgesics use by kidney transplant recipients. Ann Transplant 231:53\u2013159","journal-title":"Ann Transplant"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10862-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-10862-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10862-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T04:26:34Z","timestamp":1766895994000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-10862-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10862"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-10862-z","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"assertion":[{"value":"31 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was reviewed and approved by the Ethics Committee of Dr. Benbadis University Hospital Center, Constantine (Reference No. CE\/CHUC\/07\/01-2019). All procedures involving human participants were conducted in strict accordance with the ethical standards of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors approved.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors agree to the publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Written informed consent was obtained from all participants before inclusion in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"756"}}